Points To Consider For CV Safety Assessment Of Opioid Antagonists
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Post-marketing requirements for the two opioid antagonists approved since an advisory committee about cardiovascular risk with the class show a clear template for such studies.